Acta Scientific Microbiology (ISSN: 2581-3226)

Perspective Volume 4 Issue 2

Virus, Immunity and Human Neurodegenerative Diseases. A Perspective

Rodríguez-Leyva Ildefonso* and Jiménez-Capdeville María E

School of Medicine, Universidad Autónoma De San Luis Potosí and Neurology Department, Hospital Central “Dr. Ignacio Morones Prieto”, San Luis Potosí, S.L.P., México

*Corresponding Author: Rodríguez-Leyva Ildefonso, School of Medicine, Universidad Autónoma De San Luis Potosí and Neurology Department, Hospital Central “Dr. Ignacio Morones Prieto”, San Luis Potosí, S.L.P., México.

Received: December 08, 2020; Published: January 22, 2021

×

A century ago, von Economo described a central nervous system (CNS) disorder related to an epidemic problem, presented from 1916 to 1927. The principal affection was related to the midbrain and basal nuclei, whereby the patients showed neuropsychiatric manifestations, mainly Parkinsonism. Since then, the influenza virus was associated to these sequelae. Recently, it has been documented that Von Economo´s working hypothesis was that the immune response could affect the neuronal function through antibodies, with lymphocytic infiltration of B and T cells in peri-venous localization.

×

References

  1. Reid AH., et al. “Experimenting on the Past: The Enigma of von Economo’s Encephalitis Lethargica”. Journal of Neuropathology and Experimental Neurology 7 (2001): 663-670.
  2. Howard RS and Lees AJ. “Encephalitis lethargica: a report of four recent cases”. Brain 1 (1987): 19-33.
  3. Dale R., et al. “Encephalitis lethargica syndrome: 20 New cases and evidence of basal ganglia autoimmunity”. Brain Journal of Neurology 127 (2004): 21-33.
  4. Lutters B., et al. “The centennial lesson of encephalitis lethargica”. Neurology12 (2018): 563.
  5. Haraguchi T., et al. “An autopsy case of postencephalitic parkinsonism of von Economo type: some new observations concerning neurofibrillary tangles and astrocytic tangles”. Neuropathology 2 (2000): 143-148.
  6. Hoffman LA and Vilensky JA. “Encephalitis lethargica: 100 years after the epidemic”. Brain 8 (2017): 2246-2251.
  7. Badrfam R and Zandifar A. “From encephalitis lethargica to COVID-19: Is there another epidemic ahead?” Clinical Neurology and Neurosurgery 196 (2020): 106065.
  8. Pilotto A., et al. “The clinical spectrum of encephalitis in COVID-19 disease: the ENCOVID multicentre study”. Medrxiv (2020).
  9. Zambreanu L., et al. “A case of limbic encephalitis associated with asymptomatic COVID-19 infection”. Journal of Neurology, Neurosurgery, and Psychiatry 11 (2020): 1229.
  10. McAbee GN., et al. “Encephalitis associated with COVID-19 infection in an 11-year-old child”. Pediatric Neurology 109 (2020): 94.
  11. Ayuso LL., et al. “Bickerstaff encephalitis after COVID-19”. Journal of Neurology (2020): 1-3.
  12. Panariello A., et al. “Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report”. rain, Behavior, and Immunity 87 (2020).
  13. Monti G., et al. “Anti-NMDA receptor encephalitis presenting as new-onset refractory status epilepticus in COVID-19”. Seizure 81 (2020): 18.
  14. Pilotto A., et al. “Steroid‐responsive encephalitis in Covid‐19 disease”. Annuals of Neurology 88 (2020): 423-427.
  15. Titulaer MJ., et al. “Antibodies to NMDA and other synaptic receptors in choreoathetosis and relapsing symptoms post-Herpes Virus Encephalitis”. Movement Disorders Journal - Movement Disorder Society 1 (2014): 3.
  16. Venâncio P., et al. “Anti-N-methyl-D-aspartate receptor encephalitis with positive serum antithyroid antibodies, IgM antibodies against mycoplasma pneumoniae, and human herpesvirus 7 PCR in the CSF”. The Pediatric Infectious Disease Journal 8 (2014): 882-883.
  17. Linnoila JJ., et al. “CSF herpes virus and autoantibody profiles in the evaluation of encephalitis”. Neurology: Neuroimmunology and Neuroinflammation 4 (2016).
  18. Andersson T., et al. “NMDA‐receptor antagonist prevents measles virus‐induced neurodegeneration”. European Journal of Neuroscience1 (1991): 66-71.
  19. Zambrano A., et al. “Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1”. Journal of Alzheimer's Disease: JAD3 (2008): 259-269.
  20. Zhou L., et al. “Viruses and neurodegeneration”. Virology Journal1 (2013): 172.
  21. Huang J., et al. “Potential of SARS-CoV-2 to cause CNS infection: biologic fundamental and clinical experience”. Frontiers in Neurology 11 (2020): 659.
×

Citation

Citation: Rodríguez-Leyva Ildefonso and Jiménez-Capdeville María E. “Virus, Immunity and Human Neurodegenerative Diseases. A Perspective”. Acta Scientific Microbiology 4.2 (2021): 34-36.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor0.614

Indexed In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US